Sorrento Therapeutics Inc (NASDAQ: SRNE) announced that the U.S. Bankruptcy Court for the Southern District of Texas granted interim approval of Sorrento’s $75 million debtor-in-possession finan...
Tag: Sorrento
Sorrento Therapeutics Stock Nosedives After Filing Bankruptcy Paperwork
COVID-19 drug and vaccine developer Sorrento Therapeutics Inc (NASDAQ: SRNE) is filing for bankruptcy following a lengthy legal dispute. The biotech submitted its Chapter 11 filing, per an SEC filing,...
Sorrento Has Potential To Deliver Multiple Best-In-Class Products
Cantor Fitzgerald initiated coverage on Sorrento Therapeutics Inc (NASDAQ: SRNE) with an Overweight rating and a price target of $5. The analyst says Sorrento has the potential to deliver multiple bes...